NVAX May 2024 4.000 put
| Previous close | 0.0800 |
| Open | 0.1200 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 4.00 |
| Expiry date | 2024-05-17 |
| Day's range | 0.0800 - 0.1200 |
| Contract range | N/A |
| Volume | |
| Open interest | 772 |
ReutersNovavax's top shareholder Shah Capital ramps up efforts for board shakeup
Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was "undervalued and continues to suffer from poor profitability". The top shareholder had expressed concerns about mismanagement at the Maryland-based biotech and nominated two of its own candidates for the board last month. It had also urged Novavax to adopt a marketing strategy to target consumers who are hesitant to receive mRNA vaccines.
- Reuters
UPDATE 2-Novavax's top shareholder Shah Capital ramps up efforts for board shakeup
Hedge fund Shah Capital on Monday urged Novavax shareholders to vote against the re-election of three directors and proposals related to executive compensation, ramping up its efforts for a board shakeup at the COVID-19 vaccine maker. Shah Capital, which currently owns a near 7.5% stake in Novavax and is its third-largest shareholder, reiterated that the company was "undervalued and continues to suffer from poor profitability". The top shareholder had expressed concerns about mismanagement at the Maryland-based biotech and nominated two of its own candidates for the board last month.
GlobeNewswireShah Capital Launches Campaign Urging Stockholders to Vote AGAINST the Re-Election of All of Novavax’s Directors Up for Election at its 2024 Annual Meeting
Highlights Novavax’s Massive Untapped Value That it Believes is Being Hindered by an Overly Conservative Board and Management That Clings to Failed Strategies and Have Undermined Stockholder Value Calls for Fresh Perspectives in the Boardroom to Restore Investor Confidence in the Company Files Preliminary Proxy and Urges Stockholders to Vote AGAINST The Re-Election of all Class II Directors and AGAINST The Approval of Three of the Company’s Other Proposals at the Annual Meeting RALEIGH, N.C., Ma
